Growth hormone · BC-06
CJC-1295 (No DAC)
Research listing. Not an approved medicine.
CA$73
Estimated retail midpoint
Growth hormone
CJC-1295 (No DAC) + Ipamorelin
Research combination. Clinical benefits are not established.
An experimental combination intended to stimulate growth hormone release through complementary pathways. Benefits for muscle growth, recovery, fat reduction, and sleep are not clinically established.
Vial size
CA$140
Estimated retail midpoint, CAD
Research-use only. Not for human or veterinary administration. Availability depends on applicable regulations, including in Canada. Prices are estimates, not verified market averages. Descriptions are informational and do not imply Health Canada approval or proven clinical effectiveness. Many listed compounds are investigational or not authorized for human use in Canada.
More in Growth hormone
Growth hormone · BC-07
Ipamorelin
Research listing. Not an approved medicine.
CA$70
Estimated retail midpoint
Growth hormone · BC-09
Sermorelin
Historical medical use. Anti-aging and fitness uses have limited evidence.
CA$75
Estimated retail midpoint
Growth hormone · BC-10
GHRP-2
Research listing. Not an approved medicine.
CA$55
Estimated retail midpoint
Growth hormone · BC-11
GHRP-6
Research listing. Not an approved medicine.
CA$55
Estimated retail midpoint
Growth hormone · BC-12
Hexarelin
Research listing. Not an approved medicine.
CA$68
Estimated retail midpoint
Growth hormone · BC-13
Tesamorelin
An approved medicine for a specific indication. This listing is not a prescription or a dosing guide.
CA$110
Estimated retail midpoint